{"id":"metformin-immediate-release","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3-5","effect":"Metallic taste"},{"rate":"10-30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_fixedAt":"2026-03-30T17:24:13.038541","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and improving peripheral glucose uptake and utilization. It activates AMPK, a key metabolic regulator, and may also enhance insulin signaling in muscle and adipose tissue. The drug does not stimulate insulin secretion, making it weight-neutral and useful across a broad range of glucose levels.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:49.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Prediabetes (prevention of progression to type 2 diabetes)"}]},"_fixedFields":["modality→Biologic"],"trialDetails":[{"nctId":"NCT07372625","phase":"PHASE1","title":"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2026-02-04","conditions":"TP53 Y220C Mutation, Advanced Solid Tumors","enrollment":14},{"nctId":"NCT07436182","phase":"PHASE4","title":"Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-03-01","conditions":"Mitochondria, Metformin","enrollment":176},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT07300033","phase":"PHASE1","title":"Bioequivalence Study of Liquid Metformin (100 and 250 mg/mL) vs IR Tablets","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-05-15","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT07300020","phase":"PHASE1","title":"PK and Relative Bioavailability of Novel Liquid Metformin vs Tablets","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-04-15","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT07300059","phase":"PHASE1","title":"Short-Term Glycemic Effects of Liquid Metformin vs Standard Tablets","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-07-15","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT07300046","phase":"PHASE1","title":"Tolerability Study of Liquid Metformin (100 and 250 mg/mL) vs IR Tablets","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-06-15","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT07272967","phase":"PHASE4","title":"Metformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"Badr University","startDate":"2026-01-01","conditions":"Spinal Cord Injury (SCI)","enrollment":34},{"nctId":"NCT04545736","phase":"PHASE1, PHASE2","title":"Oral Metformin for Treatment of ABCA4 Retinopathy","status":"RECRUITING","sponsor":"National Eye Institute (NEI)","startDate":"2020-11-23","conditions":"ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy","enrollment":56},{"nctId":"NCT04625946","phase":"PHASE4","title":"Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2021-01-19","conditions":"Atrial Fibrillation","enrollment":117},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06896981","phase":"PHASE2, PHASE3","title":"Semaglutide in Women With Polycystic Ovary Syndrome and Obesity","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-02-01","conditions":"Polycystic Ovary Syndrome (PCOS) Women, Obesity","enrollment":30},{"nctId":"NCT04288778","phase":"PHASE4","title":"A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2020-11-25","conditions":"Diabetes Mellitus","enrollment":276},{"nctId":"NCT05833958","phase":"PHASE2","title":"Polypill Versus Metformin in New Onset Type 2 Diabetes","status":"WITHDRAWN","sponsor":"George Medicines PTY Limited","startDate":"2024-09","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT06519786","phase":"PHASE3","title":"Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-10-05","conditions":"Fanconi Anemia","enrollment":30},{"nctId":"NCT06452498","phase":"PHASE3","title":"Preeclampsia Intervention Netherlands","status":"NOT_YET_RECRUITING","sponsor":"Amsterdam UMC","startDate":"2024-08","conditions":"Pre-Eclampsia Onset Less Than 37 Weeks, Pre-Eclampsia, Pre-Eclampsia; Complicating Pregnancy","enrollment":180},{"nctId":"NCT04510194","phase":"PHASE3","title":"COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2021-01-01","conditions":"Covid19, SARS-CoV Infection","enrollment":1323},{"nctId":"NCT05526690","phase":"PHASE1","title":"Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-28","conditions":"Hypertension","enrollment":27},{"nctId":"NCT04854512","phase":"PHASE3","title":"Investigational Study of Delayed Release Metformin","status":"SUSPENDED","sponsor":"Anji Pharma","startDate":"2021-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":675},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT03441750","phase":"PHASE4","title":"Efficacy of Metformin in Preventing Diabetes in China","status":"COMPLETED","sponsor":"Chinese Association of Geriatric Research","startDate":"2017-04-25","conditions":"PreDiabetes","enrollment":1724},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT02395237","phase":"PHASE1","title":"COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2015-05","conditions":"Healthy","enrollment":""},{"nctId":"NCT02205528","phase":"PHASE2","title":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-18","conditions":"Diabetes, Diabetes Mellitus Type 2","enrollment":108},{"nctId":"NCT01864174","phase":"PHASE4","title":"Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-20","conditions":"Type 2 Diabetes Mellitus","enrollment":1736},{"nctId":"NCT03393208","phase":"PHASE1","title":"Glucophage Immediate Release (GIR) China Bioequivalence Study","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-01-10","conditions":"Healthy","enrollment":44},{"nctId":"NCT03967496","phase":"","title":"Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence and Etiologic Factors","status":"COMPLETED","sponsor":"Sultan Qaboos University","startDate":"2019-01-01","conditions":"Delirium, Anesthesia; Adverse Effect","enrollment":402},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT03458208","phase":"PHASE1","title":"Bioequivalence Study of Metformin 1000 mg Tablets Immediate Release (IR) Versus Glucophage® 1000 mg Tablets IR In Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-02-14","conditions":"Bioequivalence","enrollment":18},{"nctId":"NCT02526524","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT00941239","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2007-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT01119846","phase":"PHASE2","title":"A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-05","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT00519480","phase":"PHASE1","title":"A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-11","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT03208309","phase":"PHASE2","title":"Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin","status":"COMPLETED","sponsor":"ANS Pharma","startDate":"2013-01","conditions":"Complications of Diabetes Mellitus, Diabetes Mellitus, Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01725672","phase":"PHASE1","title":"Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-09-27","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT02252965","phase":"PHASE4","title":"Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2014-12","conditions":"Diabetes Mellitus, Type 2","enrollment":532},{"nctId":"NCT02984722","phase":"NA","title":"Extended-release vs Immediate-release Metformin in PCOS Women","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2016-12","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT02291510","phase":"PHASE1","title":"Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2012-10","conditions":"Healthy Subjects","enrollment":20},{"nctId":"NCT02745912","phase":"PHASE1","title":"Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT01677299","phase":"PHASE1, PHASE2","title":"Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT02206607","phase":"PHASE1","title":"Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":39},{"nctId":"NCT02177643","phase":"PHASE2","title":"Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2013-01","conditions":"Diabetes-Related Complications, Diabetes Mellitus, Type 2, Insulin Resistance","enrollment":60},{"nctId":"NCT01535677","phase":"PHASE1","title":"To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT01525225","phase":"PHASE1","title":"Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":4},{"nctId":"NCT00885378","phase":"PHASE3","title":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT00899470","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00897390","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT02221180","phase":"PHASE1","title":"Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-08","conditions":"Bioequivalence","enrollment":2},{"nctId":"NCT02220218","phase":"PHASE1","title":"Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-08","conditions":"Healthy","enrollment":2},{"nctId":"NCT02064374","phase":"PHASE1","title":"Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284},{"nctId":"NCT01454622","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-09","conditions":"Healthy","enrollment":64},{"nctId":"NCT00432276","phase":"PHASE3","title":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":803},{"nctId":"NCT01459094","phase":"PHASE1","title":"Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01508195","phase":"PHASE1","title":"A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Healthy","enrollment":64},{"nctId":"NCT01508182","phase":"PHASE1","title":"A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Healthy","enrollment":64},{"nctId":"NCT01463774","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Healthy","enrollment":74},{"nctId":"NCT01518712","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-09","conditions":"Healthy","enrollment":64},{"nctId":"NCT01463228","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Healthy","enrollment":83},{"nctId":"NCT00986401","phase":"PHASE1","title":"Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-10","conditions":"Healthy","enrollment":44},{"nctId":"NCT00809536","phase":"PHASE1","title":"Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-01","conditions":"Generalized Anxiety Disorder","enrollment":24},{"nctId":"NCT00648869","phase":"NA","title":"Open-label Crossover Metformin Gum Versus Tablet in Healthy Volunteers","status":"WITHDRAWN","sponsor":"Hadassah Medical Organization","startDate":"2008-06","conditions":"Healthy","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metformin immediate release","genericName":"Metformin immediate release","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin immediate release is a small molecule used to treat conditions such as Type 2 Diabetes Mellitus and Gestational Diabetes Mellitus. It is typically administered orally in a fixed dose combination with other medications, such as saxagliptin, for the treatment of these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}